Mosunetuzumab-axgb (Lunsumio)
Dilution requiredFull monograph review pending
U.S. label preparation
Lunsumio · Dilution required
- Preparation
- Use the IV concentrate and a bag of 0.9% or 0.45% sodium chloride. Remove the volume of diluent that the prescribed dose will replace.
- Administration and handling
- Select the bag size for the step-up or maintenance dose in Table 7. Lunsumio Velo is subcutaneous.
Product and source details
Genentech, Inc. · BLA761263
Product NDC: 50242-142, 50242-159
SPL effective 2026-06-29 | SPL version 7. Checked 2026-11-13.
Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.
Product identifiers and clinical review status
U.S. label preparation available. Full monograph review pending.
Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.
What remains to be completed
- Obtain independent corroboration of the label preparation where available.
- Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
- Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.